Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAY 41-4109 racemate 是BAY 41-4109的消旋体。BAY 41-4109有效抑制人乙型肝炎病毒,IC50值为53 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 219 | 现货 | ||
2 mg | ¥ 318 | 现货 | ||
5 mg | ¥ 578 | 现货 | ||
10 mg | ¥ 970 | 现货 | ||
25 mg | ¥ 1,830 | 现货 | ||
50 mg | ¥ 3,160 | 现货 | ||
100 mg | ¥ 4,650 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 638 | 现货 |
产品描述 | BAY 41-4109 racemate is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM. |
靶点活性 | HBV:53 nM. |
体外活性 | BAY 41-4109 is able to both accelerate and misdirect capsid assembly in vitro. BAY 41-4109 stabilized the preformed capsids, up to a ratio of one inhibitor molecule per two dimers[2]. BAY 41-4109 is equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with IC50s of 32.6 and 132 nM in HepG2.2.15 cells, respectively. HBV DNA and HBcAg are inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition[3].. |
体内活性 | BAY 41-4109 reduces viral DNA in the liver and in the plasma in a dose-dependent manner with efficacy comparable to 3TC. BAY 41 -4109 reduces hepatitis B virus core antigen (HBcAg) in livers of HBV-transgenic mice. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations, about 60% in rats and dogs[1].BAY41-4109 inhibits virus production in vivo by a mechanism that targets the viral capsid[2]. |
细胞实验 | Cellular metabolism is evaluated by MTT colorimetry. HepG2.2.15 cells are plated at a density of 2 × 103 cells per well in 96-well plates. After 8 d of treatment with different concentrations of each antiviral compound, 20 μL of MTT solution (5 g/L) are added to each well and incubated at 37°C for 4 h. Next, 150 μL of DMSO is added and stirred for 10 min to dissolve the crystals. Absorbance values are recorded at 490 nm by using an ELISA reader. The MTT values are calculated using the curve regression equation[3]. |
分子量 | 395.76 |
分子式 | C18H13ClF3N3O2 |
CAS No. | 298708-79-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (126.34 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5268 mL | 12.6339 mL | 25.2678 mL | 63.1696 mL |
5 mM | 0.5054 mL | 2.5268 mL | 5.0536 mL | 12.6339 mL | |
10 mM | 0.2527 mL | 1.2634 mL | 2.5268 mL | 6.317 mL | |
20 mM | 0.1263 mL | 0.6317 mL | 1.2634 mL | 3.1585 mL | |
50 mM | 0.0505 mL | 0.2527 mL | 0.5054 mL | 1.2634 mL | |
100 mM | 0.0253 mL | 0.1263 mL | 0.2527 mL | 0.6317 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bay 41-4109 racemate 298708-79-9 Microbiology/Virology HBV Bay 41-4109 Inhibitor Bay 41 4109 racemate inhibit Bay 414109 racemate Hepatitis B virus inhibitor